| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.2 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |